Skip to main content
. 2021 Dec 7;9(12):e26185. doi: 10.2196/26185

Table 1.

Baseline demographics.

Variable App (n=42) No app (n=41) P value
Age (years), mean (SD) 60.2 (9) 62 (9) .38
Female, n (%) 14 (33) 15 (37) .76
Race .56

Caucasian, n (%) 34 (81) 34 (83)

African American, n (%) 7 (17) 6 (15)

Other, n (%) 1 (2) 1 (2)
EFa (%), mean (SD) 37.2 (20) 38.8 (19) .73
HFpEFb, n (%) 16 (38) 19 (46) .45
Ischemic HFc, n (%) 19 (45) 29 (71) .02
NYHAd class

Class I, n (%) 1 (2) 0 (0) .41

Class II, n (%) 10 (24) 5 (12)

Class III, n (%) 23 (55) 27 (66)

Class IV, n (%) 8 (19) 9 (22)
Atrial fibrillation, n (%) 22 (52) 25 (61) .43
MIe, n (%) 10 (24) 18 (44) .05
DMf, n (%) 14 (33) 13 (32) .87
Moderate or severe renal disease, n (%) 1 (2) 2 (5) .62
Systolic BPg (mm Hg), mean (SD) 121.1 (23) 119.1 (21) .68
Sodium (mmol/L), mean (SD) 138.3 (3) 137.8 (3) .54
Hemoglobin (g/dL), mean (SD) 12.4 (2) 11.9 (2) .32
ACEIh, ARBi, ARNIj, n (%) 28 (67) 20 (49) .10
Beta blocker, n (%) 37 (88) 35 (85) .76
MRAk, n (%) 18 (43) 16 (39) .72

aEF: ejection fraction.

bHFpEF: heart failure with preserved ejection fraction.

cHF: heart failure.

dNYHA: New York Heart Association.

eMI: myocardial infarction.

fDM: diabetes mellitus.

gBP: blood pressure.

hACEI: angiotensin converting enzyme inhibitor.

iARB: angiotensin receptor blocker.

jARNI: angiotensin receptor and neprilysin inhibitor.

kMRA: mineralocorticoid receptor antagonist.